category,datetime,headline,id,image,related,source,summary,url
company,1768170600,Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion,138068851,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac
company,1768168440,"Eikon, a high-profile startup led by Merck vets, seeks an IPO",138069018,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a group of experimental cancer drugs.",https://finnhub.io/api/news?id=0f7dd1e4389e99a9efdf911f4f633e4ad7d333a56d4996bd08d86d8ac6467e56
company,1768147380,This ETF Is Proof That the Healthcare Rebound Is Real,138075157,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"Track healthcareâ€™s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.",https://finnhub.io/api/news?id=37f4d5b38f1ff502010ff587add70bfce19fea47b3f9d689eddcb7adcf089fbb
